Descripción del producto

Features:

• A highly selective α *-adrenoceptor agonist, has sedative, anxiolytic, analgesic properties
• New generation of alpha 2 agonists
• Aimed at minimizing side effects & maximizing pain relief
• Induces a unique sedative response which shows an easy transition from sleep to wakefulness
• Benefit of minimal respiratory depression
• Smooth induction & recovery
• Lower patient risk, increased comfort & safety

Indications:

• Used as sedative, anesthetic adjunct & analgesia

Dosage:

• Dosed in dogs based upon body surface area, not weight
• Recommended doses in dogs & cats are 2.5 to *0 µ/ kg IM or **5 µ/ kg IV. (BSAVA small animal formulary part A: canine & feline/ Sedation/ Immobilization protocols)
• **5 mcg/m2 IM for preanesthetic, minor sedation, short-term procedures, and analgesia
• **5 mcg/m2 IV or **0 mcg/m2 IM for deeper sedation, analgesia, and minor surgical procedures.
• Dosage for cats - *0 mcg/kg (0.*4 mg/kg) IM (0.*5 mL for *-kg cat). Oral transmucosal administration at this dose produces equivalent effects as IM injection. IV dose is ***0 mcg/kg
• Lower doses are used for short-term sedation and analgesia or when combined with other analgesic or anesthetic agents.

Presentation : *0ml vial